Doxercalciferol Injection shortage
Doxercalciferol Injection is currently listed in shortage by the FDA. The FDA lists 3 affected products. This page was last refreshed from FDA data on Sep 22, 2026.
Sanofi-Aventis is permanently stopping production of doxercalciferol injection. Other makers — including Dr. Reddy's, Eugia, Alembic, and Meitheal — still list doxercalciferol 4 mcg/2 mL injection as available.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Doxercalciferol Injection. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Dec 10, 2025Currently in shortage3 of 3 products affected.
-
Dec 10, 2025First reported to the FDA3 products first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: Sanofi-Aventis U.S. LLC 📞 800-633-1610 3 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Hectorol, Injection, 4 mcg/2 mL injection 50 multiple-dose vials (NDC 58468-0127-1) | — | — | Discontinuation of the manufacture of the drug | — |
| To Be Discontinued | Hectorol, Injection, 2 mcg/mL injection 50 single-dose vials (NDC 58468-0126-1) | — | — | Discontinuation of the manufacture of the drug | — |
| To Be Discontinued | Hectorol, Injection, 4 mcg/2 mL injection 50 single-dose vials (NDC 58468-0123-1) | — | — | Discontinuation of the manufacture of the drug | — |
These rows are manufacturer reports to the FDA for Doxercalciferol Injection — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Doxercalciferol Injection? options further down this page.
Why is Doxercalciferol Injection in shortage?
Sanofi-Aventis has made the decision to permanently stop manufacturing their brand-name version of doxercalciferol injection, sold as Hectorol. This affects three specific products they make: the 4 mcg/2 mL single-dose vials (boxes of 50), the 2 mcg/mL single-dose vials (boxes of 50), and the 4 mcg/2 mL multiple-dose vials (boxes of 50) — all of which are being discontinued.
It's worth knowing that Sanofi-Aventis did not share a specific public reason for why they made this decision — the FDA data simply notes it as a permanent discontinuation of manufacturing. This report only covers Sanofi-Aventis and their Hectorol products specifically, so it doesn't tell us anything about what other manufacturers of doxercalciferol injection may or may not have available.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Doxercalciferol Injection, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Doxercalciferol Injection?
Doxercalciferol injection is currently on the FDA drug-shortage list, and I want to walk you through what this means for you.
All three reported strengths are affected, and none currently have an available source from the manufacturer on this record: the 4 mcg/2 mL single-dose vials, the 2 mcg/mL single-dose vials, and the 4 mcg/2 mL multiple-dose vials. The reason listed for each is that the manufacturer (Sanofi-Aventis) is discontinuing production of these products. Because this is a discontinuation rather than a temporary delay, the supply problem from this maker may be permanent, and no estimated-recovery date applies.
That said, this report reflects only one manufacturer. The same medicine — doxercalciferol injection — is still listed on the market from other makers, including Dr. Reddy's, Eugia, Alembic, and Meitheal.
Here is how I would approach it:
- Do not stop, skip, or change your doses on your own. This medicine is given by a clinician, so keep your appointments.
- Ask your pharmacy or infusion center to source the same medicine from one of the other makers listed above; it may not be in local stock, but they can check wholesalers.
- Because your product is being discontinued, talk with your prescriber about a clinician-chosen plan going forward.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is general, national information and may not match your local stock.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Where else can I get Doxercalciferol Injection?
FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Doxercalciferol Injection is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Same medicine, other manufacturers (not reported short)
Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:
| Product | Strength | Form / route | Manufacturer | NDC |
|---|---|---|---|---|
| Doxercalciferol | DOXERCALCIFEROL 4 ug/2mL | Injection · Intravenous | Dr.Reddy's Laboratories Inc | 43598-0850-50 |
| Doxercalciferol | DOXERCALCIFEROL 4 ug/2mL | Injection, Solution · Intravenous | Eugia US LLC | 55150-0359-50 |
| Doxercalciferol | DOXERCALCIFEROL 4 ug/2mL | Injection, Solution · Intravenous | Alembic Pharmaceuticals Inc. | 62332-0690-30 |
| Doxercalciferol | DOXERCALCIFEROL 4 ug/2mL | Injection, Solution · Intravenous | Meitheal Pharmaceuticals Inc. | 71288-0802-03 |
Alternative dosage forms of Doxercalciferol
A different form of the same drug (for example a solution when capsules are short). A form change is a clinical decision — ask your prescriber:
Therapeutic equivalents & pricing 2 productsclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Hectorol 4 ug/2mL | Genzyme | 50 vials | — | — | Discontinued |
| Hectorol 4 ug/2mL | Genzyme | 50 vials | — | — | Discontinued |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Doxercalciferol Injection — that fall in the same broad treatment class (hyperparathyroid tx agents - vitamin d analog-type) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Identity & classification
Where does this data come from?
Other endocrinology/metabolism shortages
Doxercalciferol Injection shortage FAQs
Is Doxercalciferol Injection in shortage?
Which products are affected?
When will Doxercalciferol Injection be available again?
Can I still get Doxercalciferol somewhere?
What should I do if I take Doxercalciferol Injection?
Still have a question about the Doxercalciferol Injection shortage?
Ask a pharmacist about this shortage →View Doxercalciferol Injection on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.